Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967708 | 1.00 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4CYP19A1 | |
| SCHEMBL4365460 | 1.00 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4CYP19A1 | |
| SCHEMBL4966862 | 0.91 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNA4CYP19A1 | |
| SCHEMBL5429974 | 0.91 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNA4CYP19A1 | |
| SCHEMBL445361 | 0.82 | CYP19A1 (0.45) | CYP19A1 | |
| SCHEMBL4362945 | 0.81 | CHRNA3 (0.46) | CHRNB4CHRNA3CHRNB2CHRNA4LTA4H | |
| SCHEMBL4362951 | 0.81 | CHRNA3 (0.46) | CHRNB4CHRNA3CHRNB2CHRNA4LTA4H | |
| SCHEMBL12122986 | 0.81 | CHRNB2 (0.50) | CHRNB4CHRNA3CHRNB2CHRNA4LTA4H | |
| SCHEMBL7615460 | 0.81 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB2CHRNA4CYP19A1 | |
| SCHEMBL7615451 | 0.81 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB2CHRNA4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | CHRNB4 4751/4885CHRNA3 4628/4885CHRNB2 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.